What's in Jinnah Postgraduate Medical Centre's pipeline?

Jinnah Postgraduate Medical Centre has 13 drugs in our index: 9 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 3 in Phase 1.

Which companies overlap with Jinnah Postgraduate Medical Centre's portfolio?

Top competitors by shared drug class: Galderma R&D, University of Toronto, Peking University Shenzhen Hospital, Aesculape CRO Belgium BV, Balmoral Medical company.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/jinnah-postgraduate-medical-centre.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Jinnah Postgraduate Medical Centre — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Jinnah Postgraduate Medical Centre pipeline: 9 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

9 marketed 0 filed 0 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Dexamethasone Cyclophosphamide Pulse therapy	Dexamethasone Cyclophosphamide Pulse therapy	marketed
Bleomycin Injection	Bleomycin Injection	marketed
Crisaborole 2% Cream	Crisaborole 2% Cream	marketed
Metronidazole Topical Gel 2%	Metronidazole Topical Gel 2%	marketed	Nitroimidazole antimicrobial	Bacterial/protozoal DNA	Dermatology
Dexamethasone Azathioprine Pulse therapy	Dexamethasone Azathioprine Pulse therapy	marketed	Immunosuppressive combination therapy	Glucocorticoid receptor (dexamethasone); inosine monophosphate dehydrogenase (azathioprine)	Immunology / Rheumatology
Topical Sertaconazole 2%	Topical Sertaconazole 2%	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)	Dermatology / Infectious Disease
Methotrexate 1% Topical Gel	Methotrexate 1% Topical Gel	marketed	Antimetabolite; Immunosuppressant	Dihydrofolate reductase (DHFR)	Dermatology
Clindamycin Topical Gel 1%	Clindamycin Topical Gel 1%	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit	Dermatology
Clotrimazole 1%	Clotrimazole 1%	marketed	Imidazole antifungal	Fungal cytochrome P450 (lanosterol 14α-demethylase)	Infectious Disease

Therapeutic area mix

Dermatology · 3
Dermatology / Infectious Disease · 1
Immunology / Rheumatology · 1
Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Galderma R&D · 2 shared drug classes
University of Toronto · 2 shared drug classes
Peking University Shenzhen Hospital · 2 shared drug classes
Aesculape CRO Belgium BV · 1 shared drug class
Balmoral Medical company · 1 shared drug class
Bausch Health Americas, Inc. · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Bayer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Jinnah Postgraduate Medical Centre:

Cite this brief

Drug Landscape (2026). Jinnah Postgraduate Medical Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jinnah-postgraduate-medical-centre. Accessed 2026-05-17.